Cabizitaxel, a novel drug for castration-resistant prostate cancer

Ai Ping Zhou, Hong Fang, Chang Ling Li, Yan Sun

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Failure of the first-line drug docetaxel to the treatment of castration-resistant prostate cancer (CRPC) remains a challenge. Cabazitaxel, a novel semisynthetized taxane, shows a broad antitumor activity against tumors that are sensitive or insensitive to docetaxel. Phase III clinical trial revealed that cabazitaxel significantly improves the PSA and tumor response rate of CRPC, and prolongs the time to disease progression and overall survival time. The most common side effect is hematological toxicity and the most common nonhematological side effect is diarrhea.

Original languageEnglish
Pages (from-to)2229-2231
Number of pages3
JournalChinese Journal of New Drugs
Issue number19
StatePublished - Oct 15 2013


  • Cabazitaxel
  • Castration-resistant prostate cancer
  • Pharmacokinetic
  • Pharmacology


Dive into the research topics of 'Cabizitaxel, a novel drug for castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this